Keyphrases
Endometrial Cancer
100%
Ovarian Cancer
70%
Molecular Characterization
48%
Therapeutic Implications
48%
Copy number
38%
Single-cell RNA Sequencing (scRNA-seq)
34%
Cancer-associated Stromal Cells
32%
Prognostic Implications
32%
Risk Profile
32%
Epithelium
32%
Functional Significance
32%
Gynecologic Oncology
32%
Paclitaxel
27%
Chemoresistant
27%
High-grade Serous Ovarian Cancer (HGSOC)
27%
L1 Cell Adhesion Molecule (L1CAM)
27%
Tumor
27%
Serous
24%
Cancer Cells
23%
Microsatellite Instability-high (MSI-H)
23%
Polymerase
21%
Risk Stratification
21%
Chemotherapy
20%
Endometrioid
20%
Carboplatin
19%
Computed Tomography
19%
Epithelial Ovarian Cancer
19%
Cytoreductive Surgery
19%
Microsatellite Stable
19%
Endometrial Carcinoma
17%
USP14
16%
General Pathologist
16%
Photobiomodulation
16%
Folinic Acid
16%
Topoisomerase I Poison
16%
Submicron Particle Paclitaxel
16%
HSulf-1
16%
Ganitumab
16%
PG545
16%
Targeting Mitochondria
16%
Frozen Section
16%
Decision Algorithm
16%
Advanced Ovarian Carcinoma
16%
HTRA1
16%
Breast Cancer
16%
Prospective Randomized Trial
16%
Additional Value
16%
Plasma Samples
16%
Multi-omics Analysis
16%
Recurrence Prediction
16%
Medicine and Dentistry
Endometrial Cancer
100%
Neoplasm
57%
Ovarian Cancer
48%
Malignant Neoplasm
42%
Recurrent Disease
40%
Endometrium Carcinoma
38%
Disease
34%
Polymerase
32%
Cancer Cell
26%
Risk Stratification
24%
Immunohistochemistry
22%
Hysterectomy
21%
Cytoreductive Surgery
19%
Krukenberg Tumor
18%
Paclitaxel
18%
Carboplatin
16%
Stromal Cell
16%
Gynecological Oncology
16%
Small Intestine Obstruction
16%
Mitochondrion
16%
Randomized Controlled Trial
16%
Consultation
16%
Uterine Myomectomy
16%
Computer Assisted Tomography
16%
Personalized Medicine
16%
Pathologist
16%
Gestational Trophoblastic Disease
16%
Laparotomy
16%
Bupivacaine
16%
Cancer Therapy
16%
Protein P53
16%
DNA Mismatch Repair
16%
Bevacizumab
16%
Ataxia Telangiectasia
16%
Disease Marker
16%
Cell Line
16%
Adjuvant Therapy
16%
Gynecology
13%
Obstetrics
13%
Myoma
13%
Enhanced Recovery After Surgery
12%
Surgery
11%
Deubiquitinase
10%
Drug Resistance
10%
Cancer Stem Cell
9%
Microsatellite Instability
9%
Symptom
8%
Metastatic Carcinoma
8%
Drug Delivery System
8%
Quality of Life
8%
